Summary #

Introduction #

TNBC와 basal-like는 겹쳐진다.

Epidemiology and risk factors for TNBC #

Higher rates in

• Younger women
• BRCA1 expression
• African, Hispanic ancestry

Matastasis

• Luminal A --> late born metastasis
• TNBC --> early visceral metastasis

Limitations of current treatment strategies for TNBC #

Current treatment strategy

• chemotherapy agent (Anthracycline, Taxane, Ixabepilone)
• platinum agent
• anti-EGFR drugs

chemotherapy TNBC는 luminal A, B 보다 높은 progression-free survival 반응율을 가진다. 그러나 짧은 disease-free survival, overal survival.

Platinum salts in TNBC #

Cisplatin + Doxorubicin shows effects.

Bivacizumab #

It's for all breast cancers.

EGFR inhibitor #

Cetuximab + Paclitacel or Doxorubicin

Other potential treatment targets in TNBC #

• VEGF inhibitor Dasatinib
• check point 1 inhibitor

PARP inhibitor #

Olaparib

Androgen receptor treated target #

Expression 데이터로 clustering 했을 때, ER- 쪽에 속하는 ER+ 몇개가 있음. --> ER은 없지만, downstream 발현이 ER+와 유사, 그리고, AR 높음.

AR is widely expressed in breast cancer.

Addressing current unmet needs in clinical practice #

61개 이상의 TNBC 임상연구가 ClinicalTrails.gov에 보고됨

Conclusions #

Incoming Links #

Related Articles (Article 0) #

• Triple-negative breast cancer

Suggested Pages #

• 0.202 Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
• 0.050 CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
• 0.050 BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells
• 0.025 Mutational signature
• 0.025 Talazoparib
• 0.025 Carboplatin
• 0.025 Vascular permeability factor
• 0.025 VPF
• 0.025 January 13
• 0.025 HER2
• More suggestions...